An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Who is this study for? Patients with liver metastatic colorectal cancer and non-small cell lung cancer
What treatments are being studied? TATE+Pembrolizumab
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
• mCRC progressed on at least two lines of standard chemotherapy; or
• NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
• Measurable disease
• ECOG 0-1
• At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
• Adequate organ function
Locations
United States
California
University of California, Irvine Medical Center
RECRUITING
Orange
Other Locations
Taiwan
China Medical University Hsinchu Hospital
RECRUITING
Hsinchu
Chung Shan Medical University Hospital
RECRUITING
Taichung
Contact Information
Primary
Ray Lee, MD. PhD.
ray.lee01@teclison.com
8043341076
Backup
Chiwei Lu
chiwei.lu4@teclison.com
Time Frame
Start Date: 2021-05-20
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 110
Treatments
Experimental: colorectal cancer
metastatic colorectal cancer progressed on at least two lines of chemotherapy
Experimental: NSCLC
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
Related Therapeutic Areas
Sponsors
Collaborators: Merck Sharp & Dohme LLC
Leads: Teclison Ltd.